menu
    • menu
    [{"orgOrder":0,"company":"Therapix Biosciences","sponsor":"Evero","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2020","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Therapix Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapix Biosciences \/ Evero","highestDevelopmentStatusID":"8","companyTruncated":"Therapix Biosciences \/ Evero"},{"orgOrder":0,"company":"Therapix Biosciences","sponsor":"Therapix Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"THX-160","moa":"CB2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapix Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapix Biosciences \/ Therapix Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Therapix Biosciences \/ Therapix Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Therapix Biosciences

    Menu

    Therapix Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Therapix Biosciences

                            Israel arrow
                            Coatings Trends
                            Not Confirmed

                            Therapix Biosciences

                            Israel arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Evero

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Therapix Biosciences Closes A Joint Venture Transaction For its Sleep Indication

                            Details : As part of the joint venture, Therapix transferred to Evero its THX-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset purchase agreement.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            May 19, 2020

                            Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Evero

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Therapix Biosciences

                            Israel arrow
                            Coatings Trends
                            Not Confirmed

                            Therapix Biosciences

                            Israel arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THX-160

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : The University of Calgary

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Therapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Can...

                            Details : This collaboration is expected to facilitate the further development of THX-160 for the treatment of pain, following efficacy pre-clinical studies that demonstrated the analgesic advantages of THX-160 over control.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 12, 2020

                            Lead Product(s) : THX-160

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : The University of Calgary

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth